Cepheid

Molecular Diagnostics Market: DNA Probes and Biochips - New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers.
Nanotechnology Weekly; 11/16/2009; 747 words; ...Abbott Aclara Affymetrix Agilent Ambion Applied Biosystem ARCA Biopharma Beckman Coulter BD Biokit BioMerieux Biotest Caliper Cepheid Chiron For more information visit http://www.researchandmarkets.com/research/64550c/molecular_diagnost Keywords...

Cepheid Reports 2009 Third Quarter Results.(Financial report)
Health & Medicine Week; 11/9/2009; 509 words; Cepheid (NASDAQ: CPHD) reported revenue for...in the third quarter of 2008 (see also Cepheid). Excluding amortization of purchased...share, in the third quarter of 2008. "Cepheid continued to deliver against its aggressive...

Cepheid to Webcast Upcoming Financial Presentations.
PR Newswire; 11/5/2009; 663 words; ...Calif., Nov. 5 /PRNewswire-FirstCall/ -- Cepheid today announced that its executives will be...live webcasts for these events, please visit Cepheid's website at http://www.cepheid.com/investors at least 15 minutes before...

Other News To Note.
BIOWORLD Today; 11/4/2009; 3387 words; ...the cells to produce the active form of the Mammastatin protein. Biotherapies focuses on cancer therapies and diagnostics. Cepheid Inc., of Sunnyvale, Calif., appointed John Bishop CEO and a member of the board. Bishop is formerly president and CEO...

U.S. Patent Disclosures.
BIOWORLD Today; 11/4/2009; 1211 words; ...patients with kidney cancer or melanoma who also are receiving interleukin-2. Biomed 101 binds to the leukotriene B4 receptor. Cepheid Inc., of Sunnyvale, Calif., was issued U.S. Patent No. 6,369,893 broadly covering the company's fundamental...